136 related articles for article (PubMed ID: 30994802)
1. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.
Assis TSM; Rabello A; Cota G; Werneck GL; Azeredo-da-Silva ALF
Rev Soc Bras Med Trop; 2019 Apr; 52():e20180272. PubMed ID: 30994802
[TBL] [Abstract][Full Text] [Related]
2. The direct costs of treating human visceral leishmaniasis in Brazil.
Assis TSM; Rosa DCP; Teixeira EM; Cota G; Azeredo-da-Silva ALF; Werneck G; Rabello A
Rev Soc Bras Med Trop; 2017; 50(4):478-482. PubMed ID: 28954068
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
[TBL] [Abstract][Full Text] [Related]
4. Treatment With Liposomal Amphotericin B for All Confirmed Cases of Human Visceral Leishmaniasis in Brazil: A Budget Impact Analysis.
Silva Ferreira de Carvalho IP; Peixoto HM; Sierra Romero GA; Fernandes de Oliveira MR
Value Health Reg Issues; 2020 Dec; 23():77-84. PubMed ID: 32961526
[TBL] [Abstract][Full Text] [Related]
5. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of diagnostic tests for human visceral leishmaniasis in Brazil.
Machado de Assis TS; Azeredo-da-Silva AL; Werneck GL; Rabello A
Trans R Soc Trop Med Hyg; 2016 Aug; 110(8):464-71. PubMed ID: 27618920
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
Singh GP; Saxena RK; Priyadarshy V
J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
Olliaro P; Darley S; Laxminarayan R; Sundar S
Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of serological tests for human visceral leishmaniasis in the Brazilian scenario.
Freire ML; de Souza A; Cota G; Rabello A; Machado de Assis T
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008741. PubMed ID: 33031382
[TBL] [Abstract][Full Text] [Related]
10. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.
Sundar S; Goyal AK; More DK; Singh MK; Murray HW
Ann Trop Med Parasitol; 1998 Oct; 92(7):755-64. PubMed ID: 9924533
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case.
Gomes MAF; Medeiros LLC; Lobo FPD; Wanderley NRS; Matos APR; Jácome TDN; Monteiro MGL; Luz KG
Rev Soc Bras Med Trop; 2018; 51(3):393-396. PubMed ID: 29972577
[TBL] [Abstract][Full Text] [Related]
12. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
13. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
[TBL] [Abstract][Full Text] [Related]
14. Cost of Pediatric Visceral Leishmaniasis Care in Morocco.
Tachfouti N; Najdi A; Alonso S; Sicuri E; Laamrani El Idrissi A; Nejjari C; Picado A
PLoS One; 2016; 11(6):e0155482. PubMed ID: 27257808
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
16. Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
[TBL] [Abstract][Full Text] [Related]
18. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.
Sundar S; Gupta LB; Rastogi V; Agrawal G; Murray HW
Trans R Soc Trop Med Hyg; 2000; 94(2):200-4. PubMed ID: 10897369
[TBL] [Abstract][Full Text] [Related]
19. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
20. Drug donated for treatment of visceral leishmaniasis.
Burki T
Lancet Infect Dis; 2012 Feb; 12(2):106-7. PubMed ID: 22389914
[No Abstract] [Full Text] [Related]
[Next] [New Search]
